What laboratory tests are recommended for monitoring hepatitis C infection?

Laboratory Monitoring for Hepatitis C Infection

For chronic hepatitis C monitoring, obtain HCV RNA quantitative testing, liver function tests (ALT, AST, bilirubin, albumin), complete blood count with platelets, INR, and assess fibrosis stage using FIB-4 score or transient elastography prior to treatment, with HCV genotyping to guide therapy selection. 1, 2

Initial Diagnostic Testing

When hepatitis C is first suspected or confirmed:

• Anti-HCV antibody - Initial screening test 1
• HCV RNA quantitative assay - Confirms active infection in anti-HCV positive patients 1, 2
• HCV genotyping/subgenotyping (1a/1b) - Essential before starting antiviral treatment 1

Important caveat: Even with negative anti-HCV, test HCV RNA if acute infection is suspected or in immunosuppressed patients with unexplained liver disease, as antibodies may not yet be detectable 1, 2.

Baseline Pre-Treatment Assessment

Before initiating therapy, the following labs are mandatory 1, 3, 4:

Virologic Parameters

• Quantitative HCV RNA (baseline viral load)
• HCV genotype (if not previously done)

Liver Function Assessment

• ALT and AST (aminotransferases)
• Total bilirubin
• Albumin
• INR/Prothrombin time
• Platelet count

Fibrosis Staging (Non-invasive)

Calculate FIB-4 score using: age (years) × AST (IU/L) / [platelet count (10⁹/L) × √ALT (IU/L)] 1, 4

• FIB-4 <1.45: Excludes advanced fibrosis (90% negative predictive value)
• FIB-4 >3.25: Suggests cirrhosis (65% positive predictive value)

Alternative fibrosis markers 1:

• APRI score: (AST/upper limit normal) × 100/platelet count
  • APRI >1.5 suggests significant fibrosis
  • APRI >2 suggests cirrhosis
• Transient elastography (FibroScan): >12.5 kPa indicates cirrhosis

Additional Screening

Screen for coinfections given overlapping risk factors 3:

• HIV antibody/antigen
• Hepatitis B surface antigen (HBsAg)
• Hepatitis A antibody (vaccinate if non-immune)
• Syphilis, gonorrhea, chlamydia

During Treatment Monitoring

Modern direct-acting antiviral (DAA) regimens require minimal monitoring 4:

• No routine laboratory monitoring is required during treatment with current DAA regimens
• Exception for diabetics: Monitor for hypoglycemia symptoms (DAAs can improve glucose control)
• Exception for warfarin users: Monitor INR for subtherapeutic anticoagulation

For older interferon-based regimens (rarely used now) 5:

• Monitor at weeks 2 and 4, then every 4-8 weeks
• CBC (neutrophils, platelets, hemoglobin)
• ALT/AST
• TSH and free thyroxine every 12 weeks

Acute Hepatitis C Monitoring

If acute HCV infection is suspected 6:

• Test HCV RNA and ALT every 4-8 weeks for 6-12 months to monitor for spontaneous clearance
• Most spontaneous resolutions occur within 12-16 weeks
• If HCV RNA remains detectable at 6 months, chronic infection is established
• Treat as chronic infection if spontaneous clearance doesn't occur

Post-Treatment Assessment (SVR Confirmation)

At 12 weeks after completing therapy 1, 2, 4:

• Quantitative HCV RNA (undetectable = sustained virologic response/cure)
• Hepatic function panel (ALT, AST, bilirubin, albumin)
• Continue monitoring:
  • Diabetics: Watch for hypoglycemia
  • Warfarin users: Monitor INR
  • If transaminases remain elevated: Assess for other liver disease causes

SVR definition: Undetectable HCV RNA 12 weeks post-treatment using assay with detection limit of 10-25 IU/mL 1. This represents virologic cure with 99% durability.

Long-Term Monitoring After SVR

For patients with cirrhosis who achieve SVR 3:

• Hepatocellular carcinoma surveillance: Ultrasound and AFP every 6 months
• Varices screening: Upper endoscopy every 1-4 years if cirrhotic
• Risk of HCC and liver complications persists but is reduced compared to untreated patients

Common pitfall: Don't assume SVR eliminates all liver disease risk in cirrhotic patients—they still require HCC surveillance and monitoring for decompensation, though at lower rates than untreated individuals.